Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-09-15 19:17:27 ET · period of report 2026-09-11 · accession 0000907654-26-000097 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-15 19:17 | 2026-09-11 | ORKA | Agarwal Arjun | SVP, Fin | M - OptEx | $15.88 | +9,459 | 24.8K | +62% | +$150.2K |
| DMT | 2026-09-15 19:17 | 2026-09-11+ | ORKA | Agarwal Arjun | SVP, Fin | S - Sale+OE | $92.43 | -10.0K | 14.8K | -40% | -$926.0K |
| DMT | 2026-09-15 19:17 | 2026-09-11 | ORKA | Agarwal Arjun | SVP, Fin | M - OptEx | $0.00 | -9,459 | 58.3K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-11 | M | A | 8,000 | $12.50 | 23,312 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-11 | M | A | 1,459 | $34.39 | 24,771 | D | — | — | |
| 3 | Common | Common Stock | 2026-09-11 | S | D | 3,000 | $91.11 | 21,771 | D | — | — | (F1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.71 to $91.50, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. |
| 4 | Common | Common Stock | 2026-09-11 | S | D | 4,051 | $92.41 | 17,720 | D | — | — | (F1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.74 to $92.71, inclusive. |
| 5 | Common | Common Stock | 2026-09-11 | S | D | 2,208 | $93.26 | 15,512 | D | — | — | (F1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.775 to $93.40, inclusive. |
| 6 | Common | Common Stock | 2026-09-11 | S | D | 200 | $94.02 | 15,312 | D | — | — | (F1) These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.98 to $94.05, inclusive. |
| 7 | Common | Common Stock | 2026-09-15 | S | D | 560 | $95.71 | 14,752 | D | — | — | (F6) The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2026-09-11 | M | D | 8,000 | $0.00 | 84,917 | D | $12.50 · — to 2035-01-21 | 8,000 Common Stock | (F7) The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2026-09-11 | M | D | 1,459 | $0.00 | 58,333 | D | $34.39 · — to 2036-01-22 | 1,459 Common Stock | (F8) The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. |